An immunobioluminescence assay for gamma-gamma enolase activity in human serum and cerebrospinal fluid

Wevers, Ron A.; Theunisse, A. W. G.; Rijksen, Gert

doi:10.1016/0009-8981(88)90220-3

Cited by 6 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover c-src expression in neuroblastoma-and SCLC-cell lines correlated with neuroendocrine differentiation (Mellstrom et al, 1987) and c-src is connected to neurogenesis and neuronal differentiation (Brickel et al, 1991), as is the switch from a to y-enolase (Schmechel et al, 1980). In this connection it is very interesting that Wevers et al (1988) found in cerebrospinal fluid but not in serum from healthy individuals that 50% of NSE-ag had no enzyme activity. These data suggest that NSE-ag without enzyme activity may arise from inactivation of ychains and may be correlated with neuronal or neuroendocrine differentiation.…”

Section: Discussionmentioning

confidence: 99%

Distinction of two different classes of small-cell lung cancer cell lines by enzymatically inactive neuron-specific enolase

1993

Lung Cancer

View full text Add to dashboard Cite

Summary Neuron specific enolase (NSE) is widely used as a neuro-endoctrine marker. However the presence of NSE in many non-neuroendocrine tissues has raised questions on the specificity of NSE. We have investigated NSE immunoreactivity (NSA-ag), y-enolase activity and total enolase activity in small cell lung cancer (SCLC) (Bepler et al., 1987;Carney et al., 1985;Gazdar et al., 1985;Bepler et al., 1989a;Broers et al., 1985;Moody et al., 1985;Broers et al., 1988 NSE is widely used as a neuroendocrine marker. NSEimmuno reactivity is not only seen in neurons, but also in neuroendocrine cells present in endocrine glands and in the diffuse neuroendocrine systems of the lung, intestine, thymus and skin. NSE has been demonstrated in tumours, thought to arise from the neuroendocrine cell system, such as SCLC, neuroblastoma, carcinoid, pancreatic islet cell tumours and medullary thyroid carcinoma (Schmechel et al., 1978;Tapia et al., 1981;Wick et al., 1983). NSE is also present in erythrocytes, lymphocytes and platelets (Marangos et al., 1980b;Hullin et al., 1980) and in malignant lymphomas, testicular cancer, hypernephroma and non-small cell lung cancer (Takashi et al., 1989;Ariyoshi et al., 1983;Kuzmits et al., 1987;Pinto et al., 1989;Oka et al., 1989;Niehans et al. 1988). Such observations question the correlation between NSE and the neuroendocrine cell system (Schmechel, 1985 SCLC-cell linesThe SCLC-cell lines were generously provided by the

show abstract

Section: Discussionmentioning

confidence: 99%

Distinction of two different classes of small-cell lung cancer cell lines by enzymatically inactive neuron-specific enolase

1993

Lung Cancer

View full text Add to dashboard Cite

show abstract

“…NSE has been suggested to be useful in distinguishing stroke from mimics, an important first step in expediting the diagnostic process [150][151][152]. As an alternative to antibody capture, POCTs based on fluid phase enzymatic activities [153,154] or semisolid phase bioluminescence [155] are used for plasma NSE monitoring.…”

Section: Cornell Universitymentioning

confidence: 99%

Rapid Point-of-Care-Tests for Stroke Monitoring

2019

Organic Bioelectronics for Life Science and Healthcare

View full text Add to dashboard Cite

Stroke contributes to at least 7 million deaths annually and is the second leading cause of death globally. Ischemic stroke is the most common type of stroke where an interruption of blood flow within brain tissues can lead to cessation of brain activities. Central to existing reperfusion treatment strategies is prompt restoration of blood supply to compromised brain tissues. Existing methods of monitoring the progress of stroke evolution are limited to clinical evaluation and neuroimaging techniques. With advances in biomarker research, there is now a growing interest in the use of stroke biomarkers to guide clinical decision-making, especially for on-site biomarker measurements, to make time-sensitive decisions on stroke prognosis. This chapter presents an overview on pointof-care-tests (POCT) used to guide stroke prognosis, with the aim of shortening time-totreatment, classifying stroke subtypes and improving patient's outcome. First, the current stroke monitoring workflow is presented, which highlights gaps for an improved bedside biomarker assessment. Second, a detailed overview on the different POCTs used for

show abstract

“…NSE has been suggested to be useful in distinguishing stroke from mimics, an important first step in expediting the diagnostic process [127,128,129]. As an alternative to antibody capture, POCTs based on fluid phase enzymatic activities [130,131] or semi-solid phase bioluminescence [132] are used for plasma NSE monitoring.…”

Section: Pocts Expedite Stroke Prognosticsmentioning

confidence: 99%

Point-of-Care-Testing in Acute Stroke Management: An Unmet Need Ripe for Technological Harvest

et al. 2017

View full text Add to dashboard Cite

Stroke, the second highest leading cause of death, is caused by an abrupt interruption of blood to the brain. Supply of blood needs to be promptly restored to salvage brain tissues from irreversible neuronal death. Existing assessment of stroke patients is based largely on detailed clinical evaluation that is complemented by neuroimaging methods. However, emerging data point to the potential use of blood-derived biomarkers in aiding clinical decision-making especially in the diagnosis of ischemic stroke, triaging patients for acute reperfusion therapies, and in informing stroke mechanisms and prognosis. The demand for newer techniques to deliver individualized information on-site for incorporation into a time-sensitive work-flow has become greater. In this review, we examine the roles of a portable and easy to use point-of-care-test (POCT) in shortening the time-to-treatment, classifying stroke subtypes and improving patient’s outcome. We first examine the conventional stroke management workflow, then highlight situations where a bedside biomarker assessment might aid clinical decision-making. A novel stroke POCT approach is presented, which combines the use of quantitative and multiplex POCT platforms for the detection of specific stroke biomarkers, as well as data-mining tools to drive analytical processes. Further work is needed in the development of POCTs to fulfill an unmet need in acute stroke management.

show abstract

An immunobioluminescence assay for gamma-gamma enolase activity in human serum and cerebrospinal fluid

Cited by 6 publications

References 21 publications

Distinction of two different classes of small-cell lung cancer cell lines by enzymatically inactive neuron-specific enolase

Distinction of two different classes of small-cell lung cancer cell lines by enzymatically inactive neuron-specific enolase

Rapid Point-of-Care-Tests for Stroke Monitoring

Point-of-Care-Testing in Acute Stroke Management: An Unmet Need Ripe for Technological Harvest

Contact Info

Product

Resources

About